Compare Globus Medical Inc. Class A Common Stock (GMED) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs VNET Group Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while VNET Group Inc trades at $4.46 (market cap $1.27B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 8.1× VNET Group Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and VNET Group Inc for 16 Days on average.
| GMED | VNET | |
|---|---|---|
Market Cap | $10.25B | $1.27B |
Volume | 1,059,528 | 8,996,162 |
Sector | Health | Technology |
52-Week High | $96.82 | $14.03 |
52-Week Low | $58.33 | $4.49 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $9.76B | $4.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VNET trades at $5.26, down 1.13% with bearish technical signals. The stock faces fundamental challenges with negative net income margin (-22.18%) and ROE (-46.49%), though revenue grew to $9.95B in 2025. Recent strategic investments and AI infrastructure demand provide growth catalysts, but high leverage and negative cash flow remain concerns. Analyst consensus is moderately bullish with 62.5% buy ratings despite recent earnings misses.
The outlook balances growth potential from AI data center demand against significant financial risks. While strategic partnerships and wholesale IDC expansion offer upside, persistent losses, rising debt, and negative cash flow create substantial shareholder risk. Investors should weigh the company's positioning in China's tech infrastructure against its challenging balance sheet reality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
